tbuckley/cabot-search huggingface dataset:
PB2005 LONG TERM SURVIVORS HODGKIN'S LYMPHOMA: A SINGLE CENTER EXPERIENCE
Authors: F. Gaudio, T. Perrone, P. Curci, A.V. Russo Rossi, M. di Noi, M. Urbano, A. Piccolomo, F.E. Laddaga, S. Zucano, E. Arcuti, G. Specchia
Journal: HemaSphere (2019)

Background: Since the introduction of modern radiotherapy and combination chemotherapy, Hodgkin lymphoma (HL) has become a highly curable malignancy with 5‐year survival rates of more than 80%. However, the life expectancy and quality of life of HL survivors are reduced by the occurrence of late adverse treatment effects. Aims: This retrospective study was focused on 96 patients with newly diagnosed HL treated at the University Hospital of Bari (Italy) between 2005 and 2008. Methods: Median age at diagnosis was 35 years (range 15‐83), 33 pts (34%) presented advanced stage (III‐IV), 43 (45%) bulky disease, 45 (47%) presented B symptoms, 26 (27%) extranodal disease. First line chemotherapy was ABVD in all the patients. The median number of chemotherapy lines was 1 (1‐5), 49 patients (51%) had undergone radiotherapy Results: At the end of treatment, 75 patients (78%) were in CR, and 24 patients (25%) in PR; 18 patients (24%) relapsed after a median follow‐up of 54 months (range: 12 – 62 months); 20 (21%) underwent autologous hematopoietic stem cells transplantation, 3 (3%) allogeneic stem cell transplantation. After a median follow‐up of 12 years, 83 patients (86%) remain alive and 13 (14%) have died (4 of A second neoplasia, 1 of infection, 8 of the disease). The 10‐year Kaplan‐Meier survival estimates were 84%. Three women were pregnant and 3 healthy children were born. The most prevalent chronic conditions At last follow‐up were: overweight/obesity (65%), elevated fasting glucose (38%), high total cholesterol (34%), and hypertension (25%). Summary/Conclusion: Results of this study offer indications about how long after the initial treatment the excess deaths from causes other than Hodgkin's disease begin to occur. However, challenges remain in establishing the optimal time to begin screening for potential late complications and in developing better surveillance guidelines. Further work is also needed to identify risk factors that may predict specific late effects.
FRI0111 ASSOCIATION BETWEEN RHEUMATOID FACTOR STATUS AND DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS DUE TO INEFFECTIVENESS IN RHEUMATOID ARTHRITIS
Authors: Yoshikazu Ogawa, Nobunori Takahashi, Toshihisa Kojima, Naoki Ishiguro
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> As for the treatment of rheumatoid arthritis (RA), the influence of rheumatoid factor (RF) positivity on the long-term efficacy of tumor necrosis factor inhibitors (TNFi) is controversial. <h3>Objectives:</h3> We conducted an exploratory study in a large cohort of RA patients to evaluate the relationship between RF status and the discontinuation of TNFi treatment due to ineffectiveness in a clinical setting. <h3>Methods:</h3> This study included bio-naïve RA patients enrolled in the Tsurumai Biologic Communication Registry in Japan. The crude comparison of TNFi discontinuation due to ineffectiveness between seropositive and seronegative patients was analyzed using the cumulative incidence function of competing events and Gray test. We assessed the associations between baseline patient characteristics and discontinuation of TNFi therapy due to insufficient response using Fine-Gray proportional hazard regression. Fine-Gray proportional hazard analysis considered competing events of interest, including insufficient response, adverse event, palliation, and personal reasons. <h3>Results:</h3> Demographic and clinical characteristics of each group are described in Table 1. There was a higher discontinuation rate due to insufficient response in RF positive patients than in RF negative patients using Gray test (Figure). RF positivity was significantly predictive of the discontinuation of TNFi therapy due to ineffectiveness using Fine-Gray proportional hazard regression analysis after adjusting for baseline characteristics, including age, sex, stage, class, disease activity at baseline, methotrexate use, and prednisolone use (Table 2). <h3>Conclusion:</h3> Using Fine-Gray proportional hazard regression, we demonstrated that RF positivity was related to a higher discontinuation rate of TNFi therapy due to ineffectiveness in bio-naïve RA patients. <h3>Disclosure of Interests:</h3> Yoshikazu Ogawa: None declared, Nobunori Takahashi Speakers bureau: AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Mitsubishi Tanabe, and Pfizer. YS has received speakers' fees from Astellas, Bristol-Myers Squibb, and Ono, Toshihisa Kojima Grant/research support from: Chugai Pharmaceutical (Investigator Initiated Study), Novartis, Nippon Kayaku, Eli Lilly, Eisai, Speakers bureau: Chugai Pharmaceutical, Takeda Pharmaceutical, Pfizer, Eli Lilly Japan, Bristol Myers Squibb, Ono Pharmaceutical, Daiichi Sankyo, Astelas, UCB, Janssen Pharmaceutical, Tanabe Mitsubishi, Naoki Ishiguro Grant/research support from: AbbVie, Asahi Kasei, Astellas, Chugai, Daiichi-Sankyo, Eisai, Kaken, Mitsubishi Tanabe, Otsuka, Pfizer, Takeda, and Zimmer Biomet, Consultant for: Ono, Speakers bureau: Astellas, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Pfizer, and Taisho Toyama
Genome build information is an essential part of genomic track files
Authors: Chakravarthi Kanduri, Diana Domanska, Eivind Hovig, Geir Kjetil Sandve
Journal: Genome biology (2017)

Genomic locations are represented as coordinates on a specific genome build version, but the build information is frequently missing when coordinates are provided. We show that this information is essential to correctly interpret and analyse the genomic intervals contained in genomic track files. Although not a substitute for best practices, we also provide a tool to predict the genome build version of genomic track files.
THU0635 REAL WORLD PHYSICIAN SATISFACTION WITH SECUKINUMAB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN EUROPE
Authors: Elizabeth Holdsworth, Nicola Booth, Steve Lobosco, Olivia Massey, Amie Scott, Haijun Tian, Dorothy Keininger
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in PsA and AS, however little is known about physician satisfaction with its ability to control disease in the real world. <h3>Objectives:</h3> Assess physician satisfaction with secukinumab's ability to control disease in a real-world setting. <h3>Methods:</h3> This was a cross-sectional survey of rheumatologists and dermatologists (PsA only) in France, Germany, Italy, Spain, and UK. Data were collected from Jun-Aug 2018 via physician-completed patient record forms. Patients receiving any treatment were included in the survey. Patients receiving secukinumab &gt;1 month were included in this analysis. Physicians rated satisfaction on a 5-point scale (Very satisfied to very dissatisfied), a binary variable of satisfied/not satisfied was created by grouping "Very satisfied" and "Satisfied" responses as satisfied and "Neutral", "Dissatisfied", and "Very dissatisfied" as not satisfied. Data were reported by disease, then stratified by overall physician-rated disease severity (mild/moderate/severe) at initiation of secukinumab, prior biologic use, treatment duration, and concomitant medication. <h3>Results:</h3> 438 PsA and 277 AS patients were receiving secukinumab &gt;1month at time of data collection. Patient mean age was 46.9 years (48.2 PsA, 44.8 AS) with 35.2% female (41.8% PsA; 24.9% AS). On average, patients had received secukinumab for 8.8 months (9.2 PsA; 8.2 AS). At secukinumab initiation, 44.2% of patients were rated by their physician as severe vs. 3.5% at the current consultation (39.3% vs. 2.7% PsA; 52.0% vs. 4.7% AS). Overall, 87.6% of physicians were satisfied with the ability of secukinumab to control disease (87.9% PsA; 86.3% AS). Physicians report high satisfaction across each stratification (Table 1). <h3>Conclusion:</h3> This study provides insight into physician satisfaction with secukinumab in a real-world clinical setting. Physicians reported being highly satisfied with the ability of secukinumab to control PsA and AS disease, regardless of patient population subgroups. <h3>Disclosure of Interests:</h3> Elizabeth Holdsworth Employee of: Adelphi Real World, Nicola Booth Employee of: Adelphi Real World, Steve Lobosco Employee of: Adelphi Real World, Olivia Massey Employee of: Adelphi Real World, Amie Scott Consultant for: Novartis Pharmaceuticals Corporation, Haijun Tian Shareholder of: Novartis Pharmaceutical Corporations, Employee of: Novartis Pharmaceutical Corporations, Dorothy Keininger Shareholder of: Novartis, Employee of: Novartis
Comment on “An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness”
Authors: Carlos A. Penno, Nathalie Wack, Claire Laguerre, Franziska Hasler, Shin Numao, Till A. Röhn
Journal: Science Translational Medicine (2019)

Increased airway hyperresponsiveness and epithelial remodeling in asthmatic LTA4H-KO mice may be mediated by CysLTs rather than elevated tripeptide PGP.
NHS chief admits that bed closures need to be reversed
Authors: Gareth Iacobucci
Journal: BMJ (2019)

The NHS will need to increase the number of acute hospital beds over the next five years to meet the growing needs of the population, the head of NHS England has said.

In his keynote speech to the NHS Confederation conference in Manchester on 19 June, Simon Stevens indicated that previous cuts to hospital beds would need to be reversed, in what he described as a “significant gear shift” in assumptions about acute bed capacity.

Over the past few years some areas of England have proposed ambitious and controversial reductions …
OP0191 EPIGENETIC PROFILING OF SYNOVIAL FIBROBLASTS REVEALS STRUCTURAL DNA DYNAMICS AT DISEASE IMPLICATED CHROMOSOME REGIONS
Authors: Xiangyu Ge, Mojca Frank-Bertoncelj, Amanda Mcgovern, Gisela Orozco, Paul Martin, Caroline Ospelt, Stephen Eyre
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> One of the more striking findings from genome-wide association studies (GWAS) is how the majority of disease associated genetic variants are found within gene regulatory regions, known as enhancers. It is now well established that these enhancers regulate target genes through physical interactions. We, and others, have shown that these interactions can vary between cell types and act over long distances. Therefore, if we are to fully translate GWAS findings, we need link disease associated enhancers to their target genes, in the relevant cell types. So far we only have a limited picture in rheumatoid arthritis (RA) relevant cell types, since synovial fibroblasts (SF) have been omitted from this type of chromatin interaction analysis. <h3>Objectives</h3> Investigate dynamic Hi-C interactions in unstimulated and stimulated SF, mapping RA enhancers to their target genes, and correlating with gene expression. <h3>Methods</h3> We cultured SF from synovial tissues of RA patients. After stimulation of the SF (n=6) with 10 ng/ul TNF for 24h, Hi-C and RNA libraries were generated and sequenced on the Illumina HiSeq 4000. We called dynamic active and inactive regions of the genome (A/B compartments), mapped on RA associated enhancers, linked these to target genes and correlated the interactions with dynamic expression. <h3>Results</h3> We found a region on the chromosome 6q23, intergenic between <i>OLIG3</i> and <i>TNFAIP3</i>, with an enhancer containing SNPs associated with RA to be dynamically linked to the <i>TNFAIP3</i> gene through DNA activity, interactions and corresponding gene expression. As shown in figure 1a, the genomic region containing the RA associated variants (red square) only resides in an open, active region of DNA (black bar, compartment A) upon TNF-stimulation of the SF. This region then makes a strong interaction with the promoter of <i>TNFAIP3</i> (figure 1a) in stimulated cells, which corresponds to a more than 100-fold increase in <i>TNFAIP3</i> gene expression (figure 1b). <h3>Conclusion</h3> Using independent data, we have indicated how the RA region on 6q23 could influence the expression of <i>TNFAIP3</i>, under stimulatory conditions in SF cells. This supports previous work, where this particular 6q23 enhancer is preferentially active in RA synovium, compared to osteoarthritis, reflecting the different stimulatory conditions in each disease (Ai <i>et al. 2018</i>). We have successfully linked an RA associated enhancer to its target gene in SF, indicating how the enhancer works over a large distance to interact with and regulate the <i>TNFAIP3</i> gene. Furthermore we show that this enhancer containing RA associated SNPs is only active upon stimulation with TNF in SF. <h3>Reference</h3> [1] Ai R, et al. Nat Commun. 2018 May 15;9(1):1921 <h3>Disclosure of Interests</h3> None declared
Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer.
Authors: Michael R. Clemens, Anne Therese Keating, Oleg Gladkov, Fei Jie, Joyce Steinberg, Elaina M. Gartner, John Crown, Vladimir Ivanovich Vladimirov
Journal: Journal of Clinical Oncology (2013)

548 Background: YM155 (YM) is a small molecule survivin suppressant. In a phase I/II study of YM plus docetaxel (D) in solid tumors evidence of anti-tumor activity was observed in women with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer (mBC). Methods: This was a randomized study of YM plus D versus D as 1st line treatment in subjects with HER2 negative mBC. Eligibility criteria were: ECOG &lt; 1, no prior chemotherapy for mBC, and at least one measurable lesion. Primary endpoint was progression free survival (PFS); secondary endpoints were: objective response rate (ORR), overall survival (OS), duration of response (DOR), clinical benefit rate (CBR), time to response (TTR) and safety. YM was administered at 5 mg/m 2 /day as a 168 hr continuous infusion followed by 14 Day (d) observation and D was administered at 75 mg/m 2 over 1 hr on d1 every 21d. In the control arm, D was dosed per investigator choice q 21d. Results: 101 subjects were randomized (50 YM + D; 51 D). Median (m) age 55 (range: 25 – 79), 25% had triple negative disease, &gt; 60% had bone and lymph mets, 86% had prior therapy for BC. mPFS (days) was 251 (95%CI: 176 – 333) YM + D vs 252 (95%CI: 202-433) D (p=0.34). ORR, CBR and TTR (YM+D; D): 26% vs. 25.5%; 82% vs. 84.3% and 45 vs 59 d. OS data are immature but showed no difference (p=0.911). Adverse events [AEs (&gt; 25%)] [YM + D% vs D %]: neutropenia 83 vs 84, alopecia 62.5 vs 53, fatigue 50 vs 41.2, nausea 35.4 vs 41.2, leucopenia 27 vs 33 and dyspnoea 33 vs 14. Common (&gt;10%) serious AEs [YM + D% vs D%]: febrile neutropenia 21 vs 8 and neutropenia 10 vs 8. Conclusions: Preclinical and clinical evidence suggested the combination of YM + D may offer additional benefit to D alone in subjects with mBC. This study showed no difference in efficacy, but the combination appeared to be well tolerated. Clinical trial information: NCT01038804.
Gonadal hormone-dependent vs. -independent effects of kisspeptin signaling in the control of body weight and metabolic homeostasis
Authors: Inmaculada Velasco, Silvia León, Alexia Barroso, Francisco Ruiz-Pino, Violeta Heras, Encarnación Torres, María León, Suvi T. Ruohonen, David García-Galiano, Antonio Romero-Ruiz, Miguel A. Sánchez-Garrido, Claes Ohlsson, Juan M. Castellano, Juan Roa, Matti Poutanen, Leonor Pinilla, María J. Vázquez, Manuel Tena-Sempere
Journal: Metabolism (2019)
PS1412 POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA
Authors: C. Gruchet, S. Guidez, C. Tomowiak, G. Fouquet, A. Machet, N. Moya, F. Sabirou, A. Levy, A. Bobin, H. Gardeney, S. Bouyer, F. Bridoux, V. Javaugue, I. Azais, G. Durand, H. Avet Loiseau, X. Leleu
Journal: HemaSphere (2019)

Background: Pomalidomide in association with dexamethasone is approved for relapsed and refractory Mutiple Myeloma (RRMM) in 3 rd line and beyond based on the multicenter international phase 3MM‐003 study that demonstrated greater efficacy for Pomalidomide plus dexamethasone over high dose dexamethasone. However, MM‐003 mainly recruited RRMM with 5 prior lines +, and very few data are available regarding real life Pomalidomide‐based treatment in 3 rd and 4 th line RRMM. Aims: The aim of this study was to study efficacy and safety of Pomalidomide‐based treatment in 3 rd and 4 th line for RRMM. Methods: This study is a retrospective, multicenter study based on 108 consecutive RRMM treated with Pomalidomide‐based treatment in 3 rd and 4 th line. All assessment made according to IMWG. Results: Median age was 62.5 (range, 30–86), with 36% older than 65 years, sex ratio M/F 1.25 and ISS disease stage 2 or 3 in 58%. 100% patients received previous treatment with Bortezomib and Lenalidomide and 34,2% had previously an autologous stem cell transplantation. 52 patients (48%) had pomalidomide‐based therapy as 3 rd , and 56 (52%) as 4 th line. 74% of patients received a double‐based therapy (Pomalidomide plus Dexamethasone) and 26% received a triple based therapy (Pomalidomide, Cyclophosphamide and Dexamethasone). Overall ORR was 55%, with 25% more than VGPR including 3 complete response with Pomalidomide‐based as 3 rd line. ORR was 53% with 16% ≥ VGPR including 1 CR for Pomalidomide‐based as 4th line. With a median follow‐up of 24 months, 58% and 48% at relapsed and died, respectively, in 3 rd line, and similarly, 74% and 50% in 4 th line. The median TTP was 7 (CI95% 1.4;12.6) and 9 (6.1;11.9) months in 3 rd and 4 th line, and the median OS 17 (7.8;26.1) and 23 (12.6;33.4) months, respectively. 22% and 30% have discontinued and reduced pomalidomide‐based treatment respectively. No patient died related to adverse events. AEs leading to pomalidomide‐based modification in schema included hematological AEs in 40% and non‐hematological AEs in 12% of patients. Overall, the most common adverse events grade 3 or 4 were neutropenia (22%), anemia (11%), thrombocytopenia (7%) and infectious disease (5%). Summary/Conclusion: Pomalidomide‐based therapy demonstrates efficacy in the real life with a manageable safety profile. Further study ill look into triplet versus doublet pomalidomide‐based regimen, with a benefit expected for the former. Further prospective studies are warranted to confirm this data on a larger MM population.
Abstract 446: HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Authors: Megan L. Tigue, Toshiki Kijima, Thomas L. Prince, Kendrick H. Yim, Harvey Schwartz, Kristin Beebe, Sunmin Lee, Marek A. Budzynski, Heinric Williams, Jane B. Trepel, Lea Sistonen, Stuart Calderwood, Len Neckers
Journal: Cancer Research (2018)

Abstract Heat shock factor 1 (HSF1) is an evolutionarily conserved transcription factor that initiates the cytoprotective heat shock response (HSR) and mediates a cancer-specific transcriptional program, which is comprised of over 500 genes and has been associated with poor clinical outcomes. HSF1 is thought to be regulated by molecular chaperones, including Heat Shock Protein 90 (HSP90). The purpose of our study was to describe the interactions between molecular chaperones, such as HSP90 and HSP70, and HSF1 and to determine the mechanism(s) by which HSP90 inhibitors promote the HSR in mammalian cells. Using a combination of techniques including IP-WB, ChIP, and RT-qPCR analysis, we demonstrated that HSP90 binding to HSF1 depends on HSP90 conformation and is only readily visualized for the ATP-dependent, N-domain dimerized chaperone, a conformation rarely sampled by mammalian HSP90. We also showed that ATP-competitive, N-domain targeted HSP90 inhibitors disrupt this interaction and enhance HSF1 phosphorylation, resulting in the increased duration of HSF1 occupancy of the hsp70 promoter and significant prolongation of both the constitutive and heat-induced HSF1 transcriptional activity. While our data do not support a role for HSP90 in sequestering HSF1 monomers to suppress HSF1 transcriptional activity, as has been previously proposed, our findings do identify a noncanonical role for HSP90 in providing dynamic modulation of HSF1 activity by participating in removal of HSF1 trimers from heat shock elements in DNA, thus terminating the heat shock response. Citation Format: Megan L. Tigue, Toshiki Kijima, Thomas L. Prince, Kendrick H. Yim, Harvey Schwartz, Kristin Beebe, Sunmin Lee, Marek A. Budzynski, Heinric Williams, Jane B. Trepel, Lea Sistonen, Stuart Calderwood, Len Neckers. HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 446.
Classification of electrophysiological and morphological neuron types in the mouse visual cortex
Authors: Nathan W. Gouwens, Staci A. Sorensen, Jim Berg, Changkyu Lee, Tim Jarsky, Jonathan Ting, Susan M. Sunkin, David Feng, Costas A. Anastassiou, Eliza Barkan, Kris Bickley, Nicole Blesie, Thomas Braun, Krissy Brouner, Agata Budzillo, Shiella Caldejon, Tamara Casper, Dan Castelli, Peter Chong, Kirsten Crichton, Christine Cuhaciyan, Tanya L. Daigle, Rachel Dalley, Nick Dee, Tsega Desta, Song-Lin Ding, Samuel Dingman, Alyse Doperalski, Nadezhda Dotson, Tom Egdorf, Michael Fisher, Rebecca A. de Frates, Emma Garren, Marissa Garwood, Amanda Gary, Nathalie Gaudreault, Keith Godfrey, Melissa Gorham, Hong Gu, Caroline Habel, Kristen Hadley, James Harrington, Julie A. Harris, Alex Henry, DiJon Hill, Sam Josephsen, Sara Kebede, Lisa Kim, Matthew Kroll, Brian Lee, Tracy Lemon, Katherine E. Link, Xiaoxiao Liu, Brian Long, Rusty Mann, Medea McGraw, Stefan Mihalas, Alice Mukora, Gabe J. Murphy, Lindsay Ng, Kiet Ngo, Thuc Nghi Nguyen, Philip R. Nicovich, Aaron Oldre, Daniel Park, Sheana Parry, Jed Perkins, Lydia Potekhina, David Reid, Miranda Robertson, David Sandman, Martin Schroedter, Cliff Slaughterbeck, Gilberto Soler-Llavina, Josef Sulc, Aaron Szafer, Bosiljka Tasic, Naz Taskin, Corinne Teeter, Nivretta Thatra, Herman Tung, Wayne Wakeman, Grace Williams, Rob Young, Zhi Zhou, Colin Farrell, Hanchuan Peng, Michael J. Hawrylycz, Ed Lein, Lydia Ng, Anton Arkhipov, Amy Bernard, John W. Phillips, Hongkui Zeng, Christof Koch
Journal: Nature Neuroscience (2019)
Abstract 13516: Elevated Plasma Levels of Matrix Metalloproteinase 9 Are Associated with Sudden Cardiac Arrest in the General Population
Authors: Rasmus Havmoeller, Audrey Uy-Evanado, Carmen Teodorescu, Katherine Jerger, Dorothy Kwok, Jo Ayala, Adriana Huertas-Vazquez, Ida Chen, Kyndaron Reinier, Karen Gunson, Jonathan Jui, Sumeet S Chugh
Journal: Circulation (2012)

Introduction: Severe LV dysfunction is the mainstay for selecting candidates for SCA primary prevention with the implantable defibrillator, but improved risk stratification methods are needed. Elev...
Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)
Authors: Paula Cramer, Julia Von Tresckow, Anna-Maria Fink, Gracia Braun, Sandra Robrecht, Can Zhang, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Othman Al-Sawaf, Benedikt Pelzer, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood (2020)